NCT04494425
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: HER2-low
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 105 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior chemotherapy for advanced or metastatic breast cancer; Patients with clinically active central nervous system metastases; Patients with prior participation in a previous trastuzumab deruxtecan study
https://ClinicalTrials.gov/show/NCT04494425